Prosecution Insights
Last updated: November 04, 2026

Astrazeneca Ireland Limited

Technology area: Biotechnology & Pharmaceuticals

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready

Analysis

Astrazeneca Ireland Limited currently faces 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. This distribution indicates that the company's pharmaceutical filings are being reviewed by multiple officials, which can lead to varied prosecution timelines and outcomes depending on individual examiner approaches.

The busiest examiner for this portfolio is RAMIREZ, DELIA M, who is assigned 1 pending office action. With 2 pending actions total, the workload is evenly divided among the 2 distinct examiners. This balance means that no single examiner dominates the current prosecution strategy. Practitioners must account for the specific requirements of the 2 different art units, as each may have unique precedents or internal guidelines for biotechnology and pharmaceutical subject matter.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
2
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (50%)
Multi-statute (no §101)1 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
RAMIREZ, DELIA M 1 65.1% +56.3%
YU, DELPHINUS DOU YI 1 37.5% +71.4%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18846588 IMPROVED IGG-DEGRADING ENZYMES AND METHODS OF USE THEREOF RAMIREZ, DELIA M —
18292187 COMPOSITIONS AND METHODS FOR INHIBITING COMPLEMENT FACTOR B YU, DELPHINUS DOU YI —

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18846588 IMPROVED IGG-DEGRADING ENZYMES AND METHODS OF USE THEREOF RAMIREZ, DELIA M —
18292187 COMPOSITIONS AND METHODS FOR INHIBITING COMPLEMENT FACTOR B YU, DELPHINUS DOU YI —

Top Art Units

Art UnitApps
1652 1
1636 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18846588 IMPROVED IGG-DEGRADING ENZYMES AND METHODS OF USE THEREOF RAMIREZ, DELIA M 1652 §101§102§112 Non-Final OA — Pending Sep 12, 2024
18292187 COMPOSITIONS AND METHODS FOR INHIBITING COMPLEMENT FACTOR B YU, DELPHINUS DOU YI 1636 §103§112 Non-Final OA — Pending Mar 10, 2024

Managing Astrazeneca Ireland Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Astrazeneca Ireland Limited have?

Astrazeneca Ireland Limited has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most Astrazeneca Ireland Limited applications?

Delia M Ramirez has the most, with 1 of Astrazeneca Ireland Limited's pending office actions.

What technology area are Astrazeneca Ireland Limited's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month